Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years (vol 25, pg 1197, 2010)

被引：1

作者：

Kim, Young-Jae ^{[1
]}

Kim, Kyung-Tai ^{[1
]}

Kim, Jae-Hoon ^{[2
]}

Cha, Soon-Do ^{[3
]}

Kim, Jae Weon ^{[4
]}

Bae, Duk-Soo ^{[5
]}

Nam, Joo-Hyun ^{[6
]}

Ahn, Woong-Shick ^{[7
]}

Choi, Ho-Sun ^{[8
]}

Ng, Timothy ^{[9
]}

Bi, Dan ^{[9
]}

Ok, Jin-Ju ^{[9
]}

Descamps, Dominique ^{[9
]}

Bock, Hans L. ^{[9
]}

机构：

[1] Hanyang Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea

[2] Yonsei Univ, Dept Obstet & Gynecol, Gangnam Severance Hosp, Seoul 120749, South Korea

[3] Keimyung Univ, Dept Obstet & Gynecol, Dongsan Med Ctr, Taegu, South Korea

[4] Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seoul 110744, South Korea

[5] Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Seoul, South Korea

[6] Univ Ulsan, Dept Obstet & Gynecol, Asan Med Ctr, Seoul, South Korea

[7] Catholic Univ Korea, Dept Obstet & Gynecol, Seoul St Marys Hosp, Seoul, South Korea

[8] Chonnam Natl Univ Hosp, Dept Obstet & Gynecol, Kwangju, South Korea

[9] GlaxoSmithKline Biol, Wavre, Belgium

来源：

JOURNAL OF KOREAN MEDICAL SCIENCE | 2010年 / 25卷 / 12期

关键词：

D O I：

10.3346/jkms.2010.25.12.1831

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1831 / 1831

页数：1

共 50 条

[41] Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands
van't Klooster, T. M.
Kemmeren, J. M.
van der Maas, N. A. T.
de Melker, H. E.
VACCINE, 2011, 29 (28) : 4601 - 4607
[42] A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention
Jenkins, David
GYNECOLOGIC ONCOLOGY, 2008, 110 (03) : S18 - S25
[43] Efficacy of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years Interim Analysis of a Phase 2 Double-Blind, Randomized, Controlled Trial
Konno, Ryo
Tamura, Shinobu
Dobbelaere, Kurt
Yoshikawa, Hiroyuki
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (03) : 404 - 410
[44] Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years Results from 2 randomized controlled trials
Zhu, Fengcai
Li, Juan
Hu, Yuemei
Zhang, Xiang
Yang, Xiaoping
Zhao, Hui
Wang, Junzhi
Yang, Jianguo
Xia, Guodong
Dai, Qinyong
Tang, Haiwen
Suryakiran, Pemmaraju
Datta, Sanjoy K.
Descamps, Dominique
Bi, Dan
Struyf, Frank
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1795 - 1806
[45] Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis-inactivated Poliovirus Vaccine to Girls and Young Women
Garcia-Sicilia, Jose
Schwarz, Tino F.
Carmona, Alfonso
Peters, Klaus
Malkin, Jean-Elie
Tran, Phu M.
Behre, Ulrich
Iturbe, Enrique B.
Catteau, Gregory
Thomas, Florence
Dobbelaere, Kurt
Descamps, Dominique
Dubin, Gary
JOURNAL OF ADOLESCENT HEALTH, 2010, 46 (02) : 142 - 151
[46] Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25years: event-triggered analysis of a randomized controlled trial
Zhu, Feng-cai
Hu, Shang-Ying
Hong, Ying
Hu, Yue-Mei
Zhang, Xun
Zhang, Yi-Ju
Pan, Qin-Jing
Zhang, Wen-Hua
Zhao, Fang-Hui
Zhang, Cheng-Fu
Yang, Xiaoping
Yu, Jia-Xi
Zhu, Jiahong
Zhu, Yejiang
Chen, Feng
Zhang, Qian
Wang, Hong
Wang, Changrong
Bi, Jun
Xue, Shiyin
Shen, Lingling
Zhang, Yan-Shu
He, Yunkun
Tang, Haiwen
Karkada, Naveen
Suryakiran, Pemmaraju
Bi, Dan
Struyf, Frank
CANCER MEDICINE, 2017, 6 (01): : 12 - 25
[47] Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study
Baril, Laurence
Rosillon, Dominique
Willame, Corinne
Angelo, Maria-Genalin
Zima, Julia
van den Bosch, Judith H.
van Staa, Tjeerd
Boggon, Rachel
Bunge, Eveline
Hernandez-Diaz, Sonia
Chambers, Christina
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 491 - 491
[48] Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years
Bi, Dan
Apter, Dan
Eriksson, Tiina
Hokkanen, Mari
Zima, Julia
Damaso, Silvia
Soila, Maaria
Dubin, Gary
Lehtinen, Matti
Struyf, Frank
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1392 - 1403
[49] Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women Open follow-up of a randomized clinical trial up to 4 years post-vaccination
Konno, Ryo
Yoshikawa, Hiroyuki
Okutani, Marie
Quint, Wim
Suryakiran, Pemmaraju V.
Lin, Lan
Struyf, Frank
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1781 - 1794
[50] Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses
David, Marie-Pierre
Van Herck, Koen
Hardt, Karin
Tibaldi, Fabian
Dubin, Gary
Descamps, Dominique
Van Damme, Pierre
GYNECOLOGIC ONCOLOGY, 2009, 115 (03) : S1 - S6

← 1 2 3 4 5 →